| Name | Futura Medical |
|---|---|
| Epic | FUM |
| Isin | GB0033278473 |
| Index | AIM100 AIM350 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 2.61p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £7.92 | Debt ratio | n/a |
| Shares in issue | 304.13 | Debt-to-equity ratio | n/a |
| P/E ratio | 73.6 | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -485.47 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | 0.43 | 52-week high / low | 1.86p / 38.43p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Futura Medical |
|---|---|
| Address | Surrey Technology Centre, 40 Occam Road, Guildford, Surrey, United Kingdom, GU2 7YG |
| Telephone | +44 (0) 1483 685670 |
| Website | http://www.futuramedical.com/ |
| Director | Position |
|---|---|
| Mr Angela Hildreth | Finance Director |
| Mr Roy Davis | Non-Executive Director |
| Mr Harmesh Suniara | Non-Executive Director |
| Mr Ken James | Executive Director |
| Mr Andrew Vaughan Unitt | Senior Independent Non-Executive Director |
| Mr Alex Duggan | Interim CEO |
| Assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Reporting date | 31/12/24 | 31/12/23 | 31/12/22 |
| Intangible asssets and goodwill | n/a | n/a | n/a |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 4.09 | 2.48 | 1.16 |
| Inventory / work in progress | 0.46 | 0.34 | n/a |
| Trade and other receivables | 2.45 | 1.24 | 0.27 |
| Cash and equivalents | 6.6 | 7.71 | 4.03 |
| Other current assets and asset held for resale | n/a | 0.04 | 1.02 |
| Total of all assets | 13.59 | 11.82 | 6.47 |
| Liabilities £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Short term liabilities | 3.84 | 6.34 | -1.75 |
| Long term liabilities | 0.78 | n/a | n/a |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 4.63 | 6.34 | -1.75 |
| Net assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net assets | 8.96 | 5.48 | 8.23 |
| Equity £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Share capital | 0.61 | 0.6 | 0.58 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -64.03 | -67.35 | -63.72 |
| Share premium account | 71.24 | 71.07 | 66.55 |
| Total equity | 8.96 | 5.48 | 8.23 |
| Income £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | 1.24 | -6.96 | -6.87 |
| Pre-tax profit | 1.29 | -6.89 | -6.87 |